Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEBANON, N.H., Oct. 14, 2021 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company with an innovative proactive diagnostic screening technology for high risk kidney complications, including Diabetic Kidney Disease (DKD), today announced a collaboration with Cardinal Health (NYSE: CAH) OptiFreight® Logistics that will increase control and visibility across every transportation modality.

Journey Biosciences and Cardinal Health OptiFreight® Logistics Collaborate to Improve Long-Term Diabetes Care

Enbridge

Coca-Cola

At least one of them has been known to bring a smile to faces.

3 Top Dividend Aristocrat Stocks for $55 or Less

DUBLIN, Ohio, Oct. 12, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today its Strategic Stock Solution now serves nearly 40 hospitals and health systems nationwide, just one year after its launch. In October last year, the U.S. healthcare system faced what was one of the deadliest surges of the pandemic to date1.

Business solutions for the next public health emergency

Amgen

Activision Blizzard

Alibaba

BHP Billiton

Biogen

Cigna

Clorox

D.R. Horton

FedEx

Corning

Global Payments

Intel

Micron Technology

Newmont Mining

NetEase

Nucor

QUALCOMM

Rio Tinto plc Sponsored

Seagate Technology Holdings PLC

Skyworks Solutions

Taiwan Semiconductor Manufacturing

V.F.

Vertex Pharmaceuticals

Buying The Dip: 27 High Quality Stocks Trading At A 20%+ Discount

AbbVie

British American Tobacco

Chevron

Imperial Brands PLC

Leggett & Platt

Novartis

Red Electrica Corp SA

Swiss Re AG

AT&T

Unilever

Exxon Mobil

Kiplinger "insights for investors" online first offered a list of 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 102 Top Dividend Stocks list 7/1/21. 39 European “Dividend Aristocrats” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years of increases for U.S. companies.

Here's 14 Top Dividends On Earth At Ideal Prices For October

Earnings from the previous quarter pushed the stock down into value territory again. The company still presents a good opportunity, despite the large opioid settlement and the debt it carries.

Cardinal Health: Still Cheap Despite The Opioid Settlements

DUBLIN, Ohio, Oct. 6, 2021 /PRNewswire/ -- While demand for rheumatology care continues to grow, rheumatologists are feeling pressured by reimbursement changes, administrative duties and workforce shortages. These findings were released today in the latest edition of  Rheumatology Insights, a research-based report published by Cardinal Health Specialty Solutions.

New Cardinal Health survey explores how rheumatologists are managing current industry dynamics including changing reimbursement and impacts of COVID-19

Cardinal Health's (CAH) subsidiary to support the Canadian Healthcare system against COVID-19 with vaccination policy.

Cardinal Health's (CAH) Unit to Aid Canadian Healthcare System

AMC Networks

BorgWarner

CoreCivic

Kroger

Sturm, Ruger & Company

Vector Group

Whether they've pulled back as of late or have been depressed for a while, consider these 7 deep value stocks screaming buys. The post 7 Deep Value Stocks That Are an Even Better Buy Now After Tanking appeared first on InvestorPlace.

7 Deep Value Stocks That Are an Even Better Buy Now After Tanking

AmerisourceBergen

McKesson

Cardinal Health Inc (NYSE: CAH), McKesson Corporation (NYSE: MCK), and AmerisourceBergen Corp (NYSE: ABC), accused of U.S. addiction crisis, have struck a settlement with a tribal government, Reuters reports. As part of the deal with Cherokee Nation's territory in Oklahoma, the three companies will pay $75 million over six and half years to resolve claims linked to the opioid epidemic in the region.

Drug Distributors Ink First Opioid Settlement With Cherokee Nation

DUBLIN, Ohio, Sept. 27, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2022 on November 9 prior to the opening of trading on the New York Stock Exchange.

Cardinal Health to Webcast Discussion of First-Quarter Results for Fiscal Year 2022 on November 9

Agilent Technologies

Accenture Plc

Automatic Data Processing

Federal Agricultural

Albemarle

Allstate

Andersons

Air Products and Chemicals

Algonquin Power & Utilities

Alexandria Real Estate Equities

Artesian Resources

Atrion

Broadcom

Axis Capital

Brookfield Asset Management

BancFirst

Becton, Dickinson and Co.

Franklin Resources

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Bank of South Carolina

Bristol-Myers

C&F Financial

C.H. Robinson Worldwide

A weekly summary of dividend activity for Dividend Champions and Contenders.

Dividend Champion And Contender Highlights: Week Of September 26

Dow Inc

Walgreens

While we stand just 5% off the all-time highs, it sure doesn't feel like it. After two lousy weeks and Monday's big sell-off, when we finally hit the elusive 5% decline that took almost a year to happen, Monday's late reversal showed that once again, the “buy the dip” crowd will wade into even the largest of sell-offs to buy stocks.

Hedge Funds Dump Stocks: Move to These 5 Big Dividend Winners Now

DUBLIN, Ohio, Sept. 20, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced it has established a goal to reduce Scope 1 and Scope 2 greenhouse gas (GHG) emissions 50% by 2030.

Cardinal Health establishes goal to reduce Scope 1 and Scope 2 greenhouse gas emissions 50% by 2030

News for Cardinal Health Stock (CAH)